Active, not recruitingPhase 3NCT03754790
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genzyme, a Sanofi Company
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Fitusiran(drug)
- Enrollment
- 281 enrolled
- Eligibility
- 12 years · MALE
- Timeline
- 2019 – 2026
Study locations (30)
- Phoenix Childrens Hospital Site Number : 8400009, Phoenix, Arizona, United States
- Children's Hospital Los Angeles Site Number : 8400019, Los Angeles, California, United States
- Center for Inherited Blood Disorders (CIBD) Site Number : 8400016, Orange, California, United States
- Nemours Children's Clinic Site Number : 8400008, Jacksonville, Florida, United States
- St Joseph's Children's Hospital of Tampa Site Number : 8400002, Tampa, Florida, United States
- Rush University Medical Center -1725 W Harrison St Site Number : 8400001, Chicago, Illinois, United States
- ~Massachusetts General Hospital Site Number : 8400011, Boston, Massachusetts, United States
- University of Michigan Hospital - 1500 E Medical Center Dr Site Number : 8400012, Ann Arbor, Michigan, United States
- Alliance for Childhood Diseases Site Number : 8400007, Las Vegas, Nevada, United States
- Childrens Hospital Medical Center of Akron Site Number : 8400006, Akron, Ohio, United States
- Investigational Site Number : 0360001, Camperdown, New South Wales, Australia
- Investigational Site Number : 0360003, Prahran, Victoria, Australia
- Investigational Site Number : 0360002, Murdoch, Western Australia, Australia
- Investigational Site Number : 1240001, Montreal, Quebec, Canada
- Investigational Site Number : 1560004, Beijing, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03754790 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.